ASP Isotopes (NASDAQ:ASPI) CEO Paul Elliot Mann Sells 83,759 Shares of Stock

ASP Isotopes Inc. (NASDAQ:ASPI) CEO Paul Mann sold 83,759 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $4.10, for a total transaction of $343,411.90. Following the completion of the transaction, the chief executive officer directly owned 9,328,570 shares in the company, valued at $38,247,137. This represents a 0.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paul Elliot Mann also recently made the following trade(s):

• On Wednesday, September 2nd, Paul Mann sold 83,758 shares of ASP Isotopes stock. The stock was sold at an average price of $3.91, for a total transaction of $327,493.78.

ASP Isotopes Stock Up 7.7%

Shares of NASDAQ:ASPI opened at $4.20 on Friday. ASP Isotopes Inc. has a fifty-two week low of $3.51 and a fifty-two week high of $14.49. The company has a quick ratio of 3.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.76. The firm’s 50-day simple moving average is $4.37 and its 200-day simple moving average is $5.20. The company has a market cap of $643.90 million, a price-to-earnings ratio of -3.18 and a beta of 3.59.

ASP Isotopes (NASDAQ:ASPI) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). ASP Isotopes had a negative net margin of 427.98% and a negative return on equity of 64.99%. The firm had revenue of $5.12 million during the quarter, compared to analyst estimates of $4.47 million.

Analyst Ratings Changes

ASPI has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a report on Wednesday, June 24th. Wall Street Zen raised ASP Isotopes from a “strong sell” rating to a “sell” rating in a report on Saturday, August 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, ASP Isotopes has an average rating of “Hold” and an average price target of $13.00.

Institutional Investors Weigh In On ASP Isotopes

A number of institutional investors have recently added to or reduced their stakes in ASPI. State of Wyoming acquired a new position in shares of ASP Isotopes in the 1st quarter valued at about $29,000. Quantbot Technologies LP purchased a new stake in shares of ASP Isotopes during the third quarter valued at approximately $34,000. BNP Paribas Financial Markets boosted its position in ASP Isotopes by 84.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after buying an additional 2,548 shares during the last quarter. Stephens Inc. AR acquired a new stake in ASP Isotopes during the 1st quarter valued at approximately $44,000. Finally, Broadhurst Jeffrey B bought a new stake in shares of ASP Isotopes in the first quarter worth $44,000. Hedge funds and other institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.